Home > About Us > Faculty Directory > Youngman Oh, PhD

Youngman Oh, PhD

Youngman Oh, PhDProfessor of Pathology and Biochemistry
Director of Cancer and Metabolic Syndrome Lab
Department of Pathology
Virginia Commonwealth University Health System
Office: 804-827-1324
Fax: 804-828-7450
yoh@vcu.edu

 

Education | VCU/MCV Appointments | Professional Organizations |
Professional Service | Editorial Advisory Boards | Recent Grants |
Recent Invited Presentations
| Recent Publications

Education

Graduate Education
PhD, Cancer Biology
Stanford University
Stanford, CA   1989-1993

MS, Biology
Eastern Michigan University
Ypsilanti, MI    1985-1987

Undergraduate Education
BS, Biology
Summa cum Laude
Korea University, Seoul  1977-1984

Virginia Commonwealth University and Medical Center Appointments

Member, Virginia Bio-Technology Research Park’s Leadership Council, Virginia Commonwealth University. 2008-present

Professor, Integrative Life Sciences Program, Virginia Commonwealth
University. 2004-present

Director of Cancer and Metabolic Syndrome Lab, Dept. of Pathology, MCV Campus, Virginia Commonwealth University. 2010-present

Professor, Dept. of Biochemistry, MCV Campus, Virginia Commonwealth University. 2003-present 

Member Scientist, Massey Cancer Center, Virginia Commonwealth University. 2003-present 

Professor, Dept. of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University. 2003-present 

Professional Organizations

The Endocrine Society
American Association for Cancer Research
American Association for the Advancement of Science 
The Western Society for Pediatric Research

Back to top

Professional Service

Ad hoc reviewer and Chair of the IGFs and IGFBPs in Aging and Disease section for the Fifth International Congress of the GRS and the IGF Society, 2010.

Ad hoc reviewer and Chair of the IGF and Physiology section for the Fourth International Congress of the GRS and the IGF Society, 2008.

External Examiner Committee member of the Ph.D. thesis for National University of Singapore, 2004, 2005.

Study section member for the Congressionally Directed Medical Research Program (CDMRP) Prostate Cancer Research Program (PCRP) Peer Review panel, 2006, 2007, 2011.

Ad hoc reviewer and Scientific Advisor of the Hormone and Cancer Section for the 87th Annual Meeting of The Endocrine Society, 2005.

Scientific Reviewer on the Jeffress Memorial Trust Funds, 2010

Oregon State Medical Research Foundation Committee, 1999-2003.

Oregon Health Sciences University Research Radiation Safety Committee, 1999-2003.

Editorial Advisory Boards
American Journal of Physiology-Endocrinology and Metabolism, 2010-present
Recent Grants

Impact of MicroRNA-200 Family on Epithilial-to-Mesenchymal Transition, Invasion and Sensitivity to Radiotherapy in Prostate Cancer. (Massey Cancer Center) (PI), 2010-2011    

Molecular mechanisms of IGFBP-3 regulation on GFP78-induced anti-estrogen resistance in breast cancer   (U.S. Army Breast Cancer Career Development Award) (PI), 2009-2013    

Novel NF-kB inhibitory action of IGFBP-3 in prostate cancer: New paradigm for suppression of angiogenesis and chemoresistance (U.S. Army Prostate Cancer Research Idea Development Award) (PI), 2007-2011    

Role of CTGF/IGFBP-8 for radiation-induced fibrosis. (Massey Cancer Center) (PI), 2007-2008    

Dysregulation of the IGFBP-3/IGFBP-3 receptor axis in prostate tumorigenesis (U.S. Army Prostate Cancer Research Idea Development Award) (PI), 2004-2008

IGFBP-3 Receptor: a New Class of Cell-death Receptor in Breast Cancer  (U.S. Army Breast Cancer Research Idea Award) (PI), 2003-2007    

Back to top

Recent Invited Presentations


Invited speaker, The 84th Annual Meeting of The Endocrine Society, San Francisco, California, June 2002.

Invited speaker, International Symposium on the Functional Role of Insulin-like Growth Factor-Binding Proteins, Tuebingen, Germany, Nov. 2002.

Invited speaker, Pharmacia Distingushed Scientist Speaker Program, Tokyo, Japan, Nov, 2003.

Invited speaker, 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, Crete, Greece, Oct. 2004.

Invited speaker, International Biomedical Science Conference, Yunnan, China, Dec. 2004.

Invited speaker, The 87th Annual Meeting of The Endocrine Society, San Diego, California, June 2005.

Invited speaker, The “Era of Hope”, Department of Defense Breast Cancer Research Program Meeting, Philadelphia, Pennsylvania, June 2005.

Invited speaker, “Role of IGF system in human cancer, aging and inflammatory diseases”, Grand Rounds, State Key Laboratory of Molecular Oncology, Beijing, China, Nov. 2006.

Invited speaker, “Novel NF-­κB Inhibitory Action of IGFBP-­3 in Human Cancer: New Paradigm for Suppression of Angiogenesis, Metastasis and Chemo­/Radio-­resistance in Human Cancer Cells”, The 3rd International Congress of the GRS and the IGF Society Meeting, Kobe, Japan Nov. 2006.

Invited speaker, “A Novel Target for Asthma, COPD and Arthritis”, The 4th International Congress of the GRS and the IGF Society Meeting, Genoa, Italy, Sept. 2008.

Invited speaker, “Recent Advances in Control of Fibrotic Disorders”, The 10th Korean Society of Pediatric Nephrology Meeting (KSPN) Busan, Korea, July 2009.

Invited speaker, “New Insights on Metabolic Syndrome”, The 10th Korean Society of Pediatric Nephrology Meeting (KSPN) Busan, Korea, July 2009.

Invited speaker, “Trends of Antibody Therapy for Human Disease”, The 10th Korean Society of Pediatric Nephrology Meeting (KSPN) Busan, Korea, July 2009.

Invited speaker, “New paradigm for antitumor action of IGF binding protein-3 in prostate cancer”, 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine, Loutraki, Greece, Oct. 2009.

Invited speaker, “Therapeutic potential of IGFBP-3 for cancer and inflammatory disease: IGF-independent cross-talk and interference with NF-kB signaling” International Anatomical Sciences and Cell Biology Conference, Singapore, May, 2010.

Invited speaker, “Therapeutic potential of IGFBP-3 for cancer and metabolic syndrome”, The Korean Society of Gynecologic Endocrinology Symposium, Seoul, Korea, July. 2010.

Back to top

Recent Publications (from 98 publications)

Peer Reviewed Publications:

Jogie-Brahim S; Min H-K; Oh Y. Proteomic approach for investigation of IGF-independent actions of IGFBPs in cancer, Expert Rev. Proteomics, 2005, 2:71-86.

Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y. Insulin-like Growth Factor Binding Protein-3 Induces G1 Cell Cycle Arrest with Inhibition of Cyclin-dependent Kinase 2 and 4 in MCF-7 Human Breast Cancer Cells. Horm Metab Res. 2010, 42(3):165-172.

Ingermann AR; Yang YF; Han J; Mikami A; Garza AE; Mohanraj L; Fan L; Idowu M; Ware JL; Kim HS Lee DY; Oh Y. Identification of a novel cell death receptor mediating IGFBP-3-induced antitumor effects in breast and prostate cancer. J. Biol. Chem, 2010, 230(39): 30233-30246.

Mohanraj L; Oh Y. Targeting the IGF system in cancer: The current and future In breast cancer therapy. Recent Pat Anticancer Drug Discov. 2011, 6: 166-177.

Lee YC, Jogie-Brahim S, Lee DY; Han J; Harada A; Murphy LJ; Oh Y.  IGFBP-3 blocks the effects of asthma by negatively regulating NF-kB signaling through IGFBP-3R-mediated activation of caspases J. Biol. Chem, 2011, 286(20):17898-17909

Han J; Jogie-Brahim S; Harada A; Oh Y.  IGF binding protein-3 suppresses tumor growth through inhibition of tumor-induced NF-κB activity. Cancer Letter, 2011, 307: 200-210.

Yoo EG; Lee WJ; Kim JH; Chae HW; Hyun SE; Kim DH; Kim HS; Oh Y. Insulin-like growth factor binding protein-3 mediates high glucose-induced apoptosis by increasing oxidative stress in porcine proximal tubular epithelial cells. Endocrinology, 2011, 6: 166-177.

Mohanraj L; Oh Y., Impact of IGF System on Dietary Short Chain Fatty Acid-Induced Anti-Inflammatory and Anti-Tumor Effects, Biomedical Research, 2012, in press

Oh Y. The Insulin-like growth factor (IGF) system in chronic kidney disease: Pathophysiology and therapeutic opportunities. Kidney Research and Clinical Practice, 2012, in press

Book Chapters

Werner H; Oh Y; Roberts CT Jr. Apoptosis in breast cancer. In “Programmed Cell Death Volume II: Role in Disease, athogenesis and Prevention” Mattson MP, Estus S, Rangnekar V, eds, “Advances in Cell Aging and Gerontology “ Elsevier Science, Netherlands, 2001, vol. 6:1-22.

Walker GE; Kim H-S; Yang Y-F; Oh Y. IGF-independent effects of the IGFBP Superfamily. In “Insulin-like Growth Factor” Le Roith D, Zumkeller W, Baxter R, eds, Landes Bioscience, 2003.

Minniti G; Oh Y.  Insulin-like growth factor binding proteins in endocrine-related neoplasia. In “Endocrine Oncology’ Ethier SP, ed, “Contemporary Endocrinology" Humana Press, NJ 2000, vol. 17:215-236.

Back to top